PACIRA BIOSCIENCES, INC. Business Acquisition, Contingent Consideration, at Fair Value (Deprecated 2013-01-31)
PACIRA BIOSCIENCES, INC. (PCRX) had Business Acquisition, Contingent Consideration, at Fair Value (Deprecated 2013-01-31) of $2.00 million as of 2011-12-31, per its 10-Q filed 2012-11-01.
Discontinued › Notes › Business Combinations
us-gaap:BusinessAcquisitionContingentConsiderationAtFairValue · last filed 2012-11-01
- 2011-12-31: Business Acquisition, Contingent Consideration, at Fair Value (Deprecated 2013-01-31) $2.00M.
| Period end | Business Acquisition, Contingent Consideration, at Fair Value (Deprecated 2013-01-31) |
|---|---|
| 2011-12-31 | $2.00M 10-Q · filed 2012-11-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| MANNKIND CORP (MNKD) | United States | $1.058B | -30.41 |
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 | |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |